구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | haNK |
Overview Company | ImmunityBio, Inc. |
Overview Modality | CGT |
Overview Target | Merkel Cell Carcinoma |
Overview Indication | Melanoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Biomarker | PSMA probe, [ 68 Ga]Ga-P16-093, with low |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | biodistribution |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Non-Invasive Brain Delivery of G4 70/30 PAMAM Dendrimers via the Intranasal Route.. Effective treatment of neurological disorders remains a major clinical challenge due to the restrictive nature of the blood-brain barrier (BBB), which limits the entry of most therapeutic agents into the central nervous system (CNS). In this study, we investigated the in vivo biodistribution, safety, and CNS target… |
Clinical Safety signal | Non-Invasive Brain Delivery of G4 70/30 PAMAM Dendrimers via the Intranasal Route.. Effective treatment of neurological disorders remains a major clinical challenge due to the restrictive nature of the blood-brain barrier (BBB), which limits the entry of most therapeutic agents into the central nervous system (CNS). In this study, we investigated the in vivo biodistribution, safety, and CNS target… |
Clinical Selected reported efficacy | ORR 5% |
Clinical Reported ORR | 6% |
Clinical Reported PFS | 13.7 |
Clinical Reported OS | 20.2 |
Clinical Result source | ClinicalTrials.gov NCT03387085 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03387085 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | haNK |
Overview Company | ImmunityBio, Inc. |
Overview Modality | CGT |
Overview Target | Merkel Cell Carcinoma |
Overview Indication | Melanoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Biomarker | PSMA probe, [ 68 Ga]Ga-P16-093, with low |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | biodistribution |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Non-Invasive Brain Delivery of G4 70/30 PAMAM Dendrimers via the Intranasal Route.. Effective treatment of neurological disorders remains a major clinical challenge due to the restrictive nature of the blood-brain barrier (BBB), which limits the entry of most therapeutic agents into the central nervous system (CNS). In this study, we investigated the in vivo biodistribution, safety, and CNS target… |
Clinical Safety signal | Non-Invasive Brain Delivery of G4 70/30 PAMAM Dendrimers via the Intranasal Route.. Effective treatment of neurological disorders remains a major clinical challenge due to the restrictive nature of the blood-brain barrier (BBB), which limits the entry of most therapeutic agents into the central nervous system (CNS). In this study, we investigated the in vivo biodistribution, safety, and CNS target… |
Clinical Selected reported efficacy | ORR 5% |
Clinical Reported ORR | 6% |
Clinical Reported PFS | 13.7 |
Clinical Reported OS | 20.2 |
Clinical Result source | ClinicalTrials.gov NCT03387085 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03387085 |
추천 비교
추천 비교